Alzheimer's disease drug development pipeline: 2021

Jeffrey Cummings, University of Nevada, Las Vegas
Garam Lee, Biogen, Weston, Massachusetts
Kate Zhong, University of Nevada, Las Vegas
Jorge Fonseca, University of Nevada, Las Vegas
Kazem Taghva, University of Nevada, Las Vegas

Abstract

The number of individuals worldwide with Alzheimer's disease (AD) is growing at a rapid rate. New treatments are urgently needed. We review the current pipeline of drugs in clinical trials for the treatment of AD.